Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fatemah S Albalawi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Profiles of Drug Substances, Excipients, and Related Methodology|January 24, 2025
Dronedarone a comprehensive drug profileAhmed H Bakheit, Khaled Abdelrazaq, Hamad M Alkahtani, et al.
Pharmaceuticals (Basel, Switzerland)|July 30, 2025
Purine-Hydrazone Scaffolds as Potential Dual EGFR/HER2 InhibitorsFatemah S Albalawi, Mashooq A Bhat, Ahmed H Bakheit, et al.
Molecules (Basel, Switzerland)|September 30, 2020
A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive InhibitorHuda S Al-Salem, Md Arifuzzaman, Hamad M Alkahtani, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Profiles of Drug Substances, Excipients, and Related Methodology|January 24, 2025
Dronedarone a comprehensive drug profileAhmed H Bakheit, Khaled Abdelrazaq, Hamad M Alkahtani, et al.
Pharmaceuticals (Basel, Switzerland)|July 30, 2025
Purine-Hydrazone Scaffolds as Potential Dual EGFR/HER2 InhibitorsFatemah S Albalawi, Mashooq A Bhat, Ahmed H Bakheit, et al.
Molecules (Basel, Switzerland)|September 30, 2020
A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive InhibitorHuda S Al-Salem, Md Arifuzzaman, Hamad M Alkahtani, et al.
Pageof 1